BioNTech (NASDAQ:BNTX) Upgraded to “Outperform” at Evercore ISI

Evercore ISI upgraded shares of BioNTech (NASDAQ:BNTX) from an in-line rating to an outperform rating in a research report released on Tuesday morning, Marketbeat Ratings reports. Evercore ISI currently has $125.00 target price on the stock, up from their previous target price of $110.00.

A number of other equities analysts have also weighed in on BNTX. HSBC lifted their price objective on BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, October 7th. The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and lifted their price target for the company from $90.00 to $137.00 in a research note on Friday, November 8th. HC Wainwright restated a “buy” rating and issued a $150.00 price target on shares of BioNTech in a research note on Monday. Hsbc Global Res upgraded BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. Finally, UBS Group lifted their price objective on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a report on Wednesday, September 18th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, BioNTech currently has a consensus rating of “Moderate Buy” and an average target price of $138.79.

BioNTech Stock Up 4.4 %

BioNTech stock opened at $106.40 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The stock has a market capitalization of $25.51 billion, a price-to-earnings ratio of -50.67 and a beta of 0.26. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The business has a fifty day moving average price of $113.68 and a 200-day moving average price of $97.45.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm’s quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter last year, the business posted $0.73 EPS. Equities research analysts forecast that BioNTech will post -3.68 EPS for the current fiscal year.

Institutional Trading of BioNTech

Several large investors have recently modified their holdings of BNTX. Covestor Ltd boosted its position in BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after acquiring an additional 133 shares during the last quarter. Planning Capital Management Corp raised its stake in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after acquiring an additional 450 shares during the period. Blue Trust Inc. increased its stake in BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after buying an additional 388 shares during the period. EverSource Wealth Advisors LLC increased its stake in BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after buying an additional 252 shares during the period. Finally, GAMMA Investing LLC increased its position in shares of BioNTech by 86.9% in the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after purchasing an additional 238 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.